HEPATITIS B

This study tests a new drug called bepirovirsen in 153 people who have both HIV and chronic hepatitis B and are already on HIV treatment. The goal is to see if bepirovirsen can clear the hepatitis B virus from the body better than a placebo. Participants will continue their regul…

This study is testing a new blood test called Oncoguard Liver to see how well it detects liver cancer (hepatocellular carcinoma) in people at increased risk, such as those with cirrhosis or hepatitis B. About 3,000 participants will provide a blood sample and undergo imaging like…

This study follows about 360 people with chronic hepatitis B who had a good response to the experimental drug bepirovirsen in earlier trials. No new drug is given; researchers simply monitor whether the response lasts over time. Participants may or may not continue standard antiv…

This study gives a single dose of bepirovirsen to 32 adults with hepatitis B, some with kidney disease and some healthy. Researchers measure how much drug gets into the blood and how long it stays. The goal is to see if kidney problems change drug levels, which could affect futur…

This study looks at how the immune system behaves in people with chronic hepatitis B. Researchers are measuring different immune cells and signals to understand why some people control the virus better than others. 201 adults already enrolled in a larger hepatitis B study are pro…

This study looks at how the immune system responds to chronic hepatitis B infection. Researchers will analyze blood samples from 40 adults already enrolled in larger treatment trials. The goal is to understand why some people respond better to therapy and how the disease progress…

This observational study follows 11 patients with chronic hepatitis B and delta coinfection and liver cirrhosis who are already receiving the antiviral drug Bulevirtide. Researchers want to see if suppressing the virus reduces portal hypertension—a dangerous buildup of pressure i…